Mark Lowey

Canada needs a life sciences sector as strategic infrastructure and a regulatory system incentivizing commercialization

Mark Lowey
July 8, 2026

Canada’s life sciences sector requires a strategic overhaul to transform world-class research into domestic commercial success and improved patient access. Industry leaders argue that aligning regulatory frameworks with economic development is essential to secure national health sovereignty and compete globally.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations:
BioCanRX, Canada Health Infoway, ExCellThera, Genome Canada, Health Canada, Innovation, Science and Economic Development Canada, Johnson & Johnson MedTech, McGill University, Research Money, Stem Cell Network, and U.S. Food and Drug Administration
People:
Cate Murray, Dominique Bérubé, Geneviève Lavertu, Rob Annan, and Stéphanie Michaud
Topics:
biomanufacturing, biotechnology, clinical trials, Commercialization, economic growth, health data, health innovation, life sciences, procurement, Regulatory reform, strategic infrastructure, and Translational research

Other News

The Short Report: July 1, 2026

A new model for strengthening Canada’s manufacturing future

If Canada measures open banking by switching, it will declare failure on a system that's actually working

Leveraging Canada’s rich health data to benefit Canadians and the economy requires sharing that data







Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.